whooping cough
Conditions
Interventions
The study group will receive an DTaP-IPV booster vaccine, with reduced D and
monovalent aP content vaccine during the third trimester of pregnancy.
Sponsors
Groene Hart Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Zie protocol pagina 16
Exclusion criteria
Exclusion criteria: Zie protocol pagina 16
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Feasibility: a. Part 1. Determination of pertussis specific antibody responses and persistence in mother and child after vaccination of the mother during pregnancy. Antibody titres of women vaccinated during pregnancy will be measured and compared with data from an ongoing study on titres in pregnant women not vaccinated during the study and with data on titres of pregnant women who have recently been infected with B. pertussis. b. Part 2. Determination of transplacental transfer of different antibodies against B. pertussis and the decline of these antibodies in the infant post natal. 2. Safety: a. Part 1. Rate of adverse events in pregnant women after immunization (using the WHO criteria). b. Part 2. Rate of adverse events after immunization in infants of vaccinated mothers. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The number of infections with B. pertussis in infants and mothers after maternal vaccination until the first year after birth. 2. The course of antibody-titers in infants of vaccinated mothers will be studied before and after routine childhood vaccination. 3. Antibody-titers to diphtheria, tetanus and polio will be measured. | — |
Countries
Netherlands
Outcome results
None listed